ClinicalTrials.gg
CompletedNCT01695135Updated Jul 18, 2019Results posted

A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

A Phase 3 interventional study of Abiraterone acetate and Placebo in Prostate Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 11 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-18.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
16th of 98
214 · median 56
Started
2012
with 6 others
Phase 3
11 of 98
2 open now
Registered
24th of 98
by date
Lead sponsor
13 of 98
Janssen Research & Development, LLC

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 16th largest by enrollment, is one of 7 that started in 2012, is one of 11 in phase 3, and was the 24th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate when co-administered with prednisone in Asian patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed docetaxel-based chemotherapy.

Read the detailed description

This is a randomized (the treatment group is assigned by chance), double-blind (neither physician nor patient knows the treatment that the patient receives) placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study with a randomization allocation ratio of 2:1 between the abiraterone acetate group (abiraterone acetate plus prednisone) and the placebo group (placebo plus prednisone). Approximately 200 (133 in the abiraterone acetate group and 67 in the placebo group) medically or surgically castrated male patients with mCRPC who have failed docetaxel-based chemotherapy will be enrolled in this study for up to 27 months. The study protocol includes the following phases: screening (within 28 days prior to randomization on Cycle 1 Day 1), double-blind treatment (28-day cycles until protocol-defined disease progression or unacceptable toxicity), and survival follow-up (up to Month 60). During the follow-up phase, patients with disease progression will be provided open-label (identity of assigned study drug will be known) extension treatment with abiraterone acetate. In the event of a positive study result at the time of the final analysis, participants in the placebo group who have not shown progressive disease in the double-blind treatment Phase of the study will be enrolled in an open-label extension treatment with abiraterone acetate treatment based on the participant's choice and treating physician's endorsement if they meet the criteria for subsequent abiraterone acetate. Abiraterone acetate 1000 mg tablets or placebo will be taken orally (by mouth) once daily plus prednisone 5 mg tablet orally twice daily. Efficacy and safety will be monitored throughout the study.

03

Conditions studied

  • Prostate Neoplasms

Browse trials for

Keywords

  • Prostate neoplasms
  • Prostate cancer
  • Metastatic castration resistant prostate cancer
  • Abiraterone acetate
  • JNJ-212082
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate except neuroendocrine carcinoma including small cell carcinoma
  • Disease progressed on or after prior docetaxel-containing chemotherapy
  • Prior 1 or 2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer, at least 1 of which contains docetaxel
  • Documented prostate cancer progression as documented by prostate specific antigen progression according to Prostate Specific Antigen Working Group criteria or radiographic progression in soft tissue or bone
  • Surgically or medically castrated, with serum testosterone level \<50 ng/dL (1.7 nmol/L)
  • performance status score of \<=2
  • Protocol-defined laboratory values
  • Agrees to protocol-defined use of effective

Exclusion criteria

Exclusion Criteria:

  • Active infection or other medical condition that would make prednisone () use
  • Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone twice daily
  • Pathological finding consistent with neuroendocrine carcinoma of prostate including small cell carcinoma
  • Uncontrolled hypertension (systolic BP >=160 mmHg or diastolic BP >=95 mmHg; patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy)
  • Active or symptomatic viral hepatitis or chronic liver disease, have a known infection with and/or virus or virus
  • History of pituitary or adrenal dysfunction.
  • heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or Class III or IV heart disease or cardiac measurement of \<50% at baseline
  • Atrial fibrillation, or other cardiac arrhythmia requiring therapy
  • Other within past 3 years (except basal or nonmetastatic squamous cell carcinoma of the skin)
  • Known
  • Prior therapy with abiraterone acetate or other CYP17 inhibitor(s), or agent(s) targeting the androgen receptor for prostate cancer
  • Prior therapy with ketoconazole for prostate cancer
  • Surgery or local prostatic intervention within 30 days of the first dose
  • Radiotherapy, chemotherapy, or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of Cycle 1 Day 1
  • Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a National Cancer Institute- grade of \<=1 (chemotherapy induced alopecia and grade 2 peripheral neuropathy is allowed)
  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Cycle 1 Day 1
  • Anti-androgen treatment must not be given within 4 weeks (flutamide) or 6 weeks (bicalutamide or nilutamide) prior to Cycle 1 Day 1
  • Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole) within 4 weeks prior to Cycle 1 Day 1
  • Has known allergies, , or intolerance to abiraterone acetate or its
  • Has contraindications to the use of prednisone per local prescribing information
  • Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate plus prednisone

    Drug: Abiraterone acetate · Drug: Prednisone

  • Experimental
    Placebo plus prednisone

    Drug: Placebo · Drug: Prednisone

Interventions

  • Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

  • DrugPlacebo

    Placebo (4 tablets) taken orally once daily

  • Prednisone 5 mg tablet taken orally twice daily

06

What researchers measure

Primary outcomes

  1. DB Phase: Time to Prostate-Specific Antigen Progression (PSA)

    Time to PSA progression was defined as time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the Prostate Specific Antigen Working Group (PSAWG) criteria. PSAWG criteria- Decline from baseline and reach response criteria: greater than or equal to (\>=) 50 percent (%) increase over the nadir and the increase in the absolute-value by at least 5 nanogram per milliliter (ng/mL) (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.

    Time frame: Up to 1.8 years

Secondary outcomes

  1. DB Phase: Overall Survival

    Overall survival was defined as the time interval from the date of randomization to the date of death from any cause.

    Time frame: From randomization to the date of death due to any cause (up to approximately 3.8 years)

  2. DB Phase: Percentage of Participants Who Achieved PSA Response

    Percentage of participants who achieved PSA response (defined as \>= 50% PSA decline from baseline) according to PSAWG criteria were reported. PSAWG criteria- Decline from baseline and reach response criteria: \>= 50% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.

    Time frame: Approximately up to 3.8 years

  3. DB Phase: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

    Time frame: Approximately up to 3.8 years

  4. DB Phase: Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire: Total Scores at the End of Treatment

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS) (Range 1-156, higher scores better). The FACT-General (FACT-G) is a 28 item Quality of Life (QOL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional (0-24) Well-being. The total range was between 1-108, higher scores better. Functional Assessment of Cancer Therapy-Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Cancer subscale scores; a sensitive measure of patient-reported health (Range 1-104, higher scores better). PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better).

    Time frame: Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])

  5. DB Phase: Time to Pain Progression

    Time to Pain progression calculated as number of days from date of randomization to date of pain progression. Pain progression- worsening of pain due to metastatic bone disease defined as increase of \>=30% in worst pain over past 24 hours on BPI-SF numeric rating scale at 2 consecutive evaluations 4 weeks apart without decrease in analgesic usage score (in 2 corresponding consecutive evaluation in analgesic usage score, if there is missing visit, use existing visit only) or increase in analgesic usage score \>=30% at 2 consecutive evaluations 4 weeks apart. BPI-SF is 11-item questionnaire which includes 4 questions that assess pain intensity and 7 questions that assess impact of pain on daily functions. Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores= greater pain. Analgesic usage was scored on scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain.

    Time frame: Approximately up to 3.8 years

  6. DB Phase: Percentage of Participants Experiencing Pain Palliation

    Percentage of participants experiencing pain palliation were reported. A participant is responder if experienced \>=30% reduction in Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity score over 24 hours observed at 2 consecutive evaluations 4 weeks apart without any increase in analgesic usage score (best response). Analgesic usage was scored on a scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions. It includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

    Time frame: Approximately up to 3.8 years

  7. DB Phase: Change From Baseline in Brief Fatigue Inventory (BFI) Score at End of Treatment

    The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. BFI has nine items. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people, and enjoyment of life. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes." BFI Total Score is the average of the nine items, ranging from 0 (no fatigue) to 10 (high fatigue).

    Time frame: Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])

07

Results

Posted Jul 18, 2019

Participant flow

A total of 214 participants were enrolled in the study (143 participants in abiraterone acetate group and 71 participants in placebo group).

Double-blind Treatment Phase
Participant flow — Double-blind Treatment Phase
MilestonePlacebo + Prednisone (Double-blind [DB])Abiraterone Acetate + Prednisone (Double-blind)Placebo + Prednisone (DB) to AA + Prednisone (Open-label)AA + Prednisone to AA + Prednisone (Open-label)
Started7114300
Completed0400
Not completed7113900
Withdrew: Progressive disease5011000
Withdrew: Withdrawal by subject61400
Withdrew: Adverse event7700
Withdrew: Other1300
Withdrew: Physician decision6300
Withdrew: Death1100
Withdrew: Noncompliance with study drug0100
Open Label Extension Treatment Phase
Participant flow — Open Label Extension Treatment Phase
MilestonePlacebo + Prednisone (Double-blind [DB])Abiraterone Acetate + Prednisone (Double-blind)Placebo + Prednisone (DB) to AA + Prednisone (Open-label)AA + Prednisone to AA + Prednisone (Open-label)
Started004980
Completed00910
Not completed004070
Withdrew: Progressive disease001322
Withdrew: Withdrawal by subject00616
Withdrew: Adverse event001116
Withdrew: Other0047
Withdrew: Physician decision0041
Withdrew: Death0027
Withdrew: Noncompliance with study drug0001

Outcome measures

PrimaryDB Phase: Time to Prostate-Specific Antigen Progression (PSA)

Time to PSA progression was defined as time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the Prostate Specific Antigen Working Group (PSAWG) criteria. PSAWG criteria- Decline from baseline and reach response criteria: greater than or equal to (\>=) 50 percent (%) increase over the nadir and the increase in the absolute-value by at least 5 nanogram per milliliter (ng/mL) (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.

Time frame:
Up to 1.8 years
Reported as:
Median · Days
DB Phase: Time to Prostate-Specific Antigen Progression (PSA)
DaysPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
DB Phase: Time to Prostate-Specific Antigen Progression (PSA)84.00 (31.00 to 113.00)169.00 (141.00 to 197.00)
Statistical analysis
  • Placebo + Prednisone (Double-blind) vs Abiraterone Acetate + Prednisone (Double-blind) · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.528 · 95% CI 0.376 to 0.740
SecondaryDB Phase: Overall Survival

Overall survival was defined as the time interval from the date of randomization to the date of death from any cause.

Time frame:
From randomization to the date of death due to any cause (up to approximately 3.8 years)
Reported as:
Median · Days
DB Phase: Overall Survival
DaysPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
DB Phase: Overall Survival561.00 (352.00 to 787.00)579.00 (504.00 to 731.00)
SecondaryDB Phase: Percentage of Participants Who Achieved PSA Response

Percentage of participants who achieved PSA response (defined as \>= 50% PSA decline from baseline) according to PSAWG criteria were reported. PSAWG criteria- Decline from baseline and reach response criteria: \>= 50% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.

Time frame:
Approximately up to 3.8 years
Reported as:
Number · Percentage of Participants
DB Phase: Percentage of Participants Who Achieved PSA Response
Percentage of ParticipantsPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
DB Phase: Percentage of Participants Who Achieved PSA Response18.354.5
SecondaryDB Phase: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

Time frame:
Approximately up to 3.8 years
Reported as:
Number · Percentage of Participants
DB Phase: Objective Response Rate (ORR)
Percentage of ParticipantsPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
DB Phase: Objective Response Rate (ORR)4.217.5
SecondaryDB Phase: Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire: Total Scores at the End of Treatment

FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS) (Range 1-156, higher scores better). The FACT-General (FACT-G) is a 28 item Quality of Life (QOL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional (0-24) Well-being. The total range was between 1-108, higher scores better. Functional Assessment of Cancer Therapy-Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Cancer subscale scores; a sensitive measure of patient-reported health (Range 1-104, higher scores better). PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better).

Time frame:
Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])
Reported as:
Mean · Units on a scale
DB Phase: Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire: Total Scores at the End of Treatment
Units on a scalePlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
Total Score-19.9 ± 22.07-16.1 ± 22.74
Physical Well-being-6.7 ± 6.52-4.9 ± 6.85
Functional Well-being-5.1 ± 6.60-2.7 ± 7.31
Emotional Well-being-2.1 ± 4.48-2.4 ± 4.87
Social Well-being-0.8 ± 3.82-1.2 ± 6.55
FACT-G Total Score-14.6 ± 16.25-11.2 ± 17.19
Prostate Cancer Subscale (PCS)-5.3 ± 7.99-4.9 ± 7.70
Treatment Outcome Index (FACT-TOI)-17.1 ± 17.76-12.5 ± 17.52
SecondaryDB Phase: Time to Pain Progression

Time to Pain progression calculated as number of days from date of randomization to date of pain progression. Pain progression- worsening of pain due to metastatic bone disease defined as increase of \>=30% in worst pain over past 24 hours on BPI-SF numeric rating scale at 2 consecutive evaluations 4 weeks apart without decrease in analgesic usage score (in 2 corresponding consecutive evaluation in analgesic usage score, if there is missing visit, use existing visit only) or increase in analgesic usage score \>=30% at 2 consecutive evaluations 4 weeks apart. BPI-SF is 11-item questionnaire which includes 4 questions that assess pain intensity and 7 questions that assess impact of pain on daily functions. Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores= greater pain. Analgesic usage was scored on scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain.

Time frame:
Approximately up to 3.8 years
Reported as:
Median · Days
DB Phase: Time to Pain Progression
DaysPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
DB Phase: Time to Pain Progression169.00 (85.00 to 253.00)505.00 (365.00 to NA)
SecondaryDB Phase: Percentage of Participants Experiencing Pain Palliation

Percentage of participants experiencing pain palliation were reported. A participant is responder if experienced \>=30% reduction in Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity score over 24 hours observed at 2 consecutive evaluations 4 weeks apart without any increase in analgesic usage score (best response). Analgesic usage was scored on a scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions. It includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Time frame:
Approximately up to 3.8 years
Reported as:
Number · Percentage of Participants
DB Phase: Percentage of Participants Experiencing Pain Palliation
Percentage of ParticipantsPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
DB Phase: Percentage of Participants Experiencing Pain Palliation31.854.5
SecondaryDB Phase: Change From Baseline in Brief Fatigue Inventory (BFI) Score at End of Treatment

The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. BFI has nine items. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people, and enjoyment of life. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes." BFI Total Score is the average of the nine items, ranging from 0 (no fatigue) to 10 (high fatigue).

Time frame:
Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])
Reported as:
Mean · Units on a scale
DB Phase: Change From Baseline in Brief Fatigue Inventory (BFI) Score at End of Treatment
Units on a scalePlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)
Fatigue Now2.4 ± 3.591.7 ± 3.34
Usual Fatigue2.4 ± 3.531.5 ± 3.18
Worst Fatigue2.6 ± 3.731.6 ± 3.49
General Activity2.3 ± 3.651.7 ± 3.38
Mood2.7 ± 3.391.8 ± 3.40
Walking Ability2.4 ± 3.281.8 ± 3.50
Normal Work2.2 ± 3.842.0 ± 3.71
Relations with Other People2.0 ± 3.081.6 ± 3.25
Enjoyment of Life2.5 ± 3.331.9 ± 3.64

Adverse events

Collected over Approximately up to 3.8 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Prednisone (Double-blind)—20/71 (28.2%)62/71 (87.3%)
Abiraterone Acetate + Prednisone (Double-blind)—33/143 (23.1%)134/143 (93.7%)
Placebo + Prednisone (DB) to AA + Prednisone (Open-label)—25/49 (51%)35/49 (71.4%)
AA + Prednisone to AA + Prednisone (Open-label)—41/80 (51.3%)54/80 (67.5%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)Placebo + Prednisone (DB) to AA + Prednisone (Open-label)AA + Prednisone to AA + Prednisone (Open-label)
Disease progressionGeneral disorders5/716/1438/4917/80
AnaemiaBlood and lymphatic system disorders0/713/1432/495/80
Lung infectionInfections and infestations0/712/1433/494/80
PyrexiaGeneral disorders1/711/1431/494/80
Multi-organ failureGeneral disorders0/711/1432/493/80
Bone painMusculoskeletal and connective tissue disorders2/713/1432/493/80
Respiratory failureRespiratory, thoracic and mediastinal disorders2/710/1430/492/80
DeathGeneral disorders0/710/1430/492/80
Platelet count decreasedInvestigations0/710/1430/492/80
FatigueGeneral disorders0/710/1431/490/80
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)Placebo + Prednisone (DB) to AA + Prednisone (Open-label)AA + Prednisone to AA + Prednisone (Open-label)
AnaemiaBlood and lymphatic system disorders16/7138/14313/4929/80
HypokalaemiaMetabolism and nutrition disorders10/7139/1438/4914/80
Bone painMusculoskeletal and connective tissue disorders15/7136/1436/494/80
Aspartate aminotransferase increasedInvestigations12/7129/1437/499/80
Pain in extremityMusculoskeletal and connective tissue disorders11/7117/1432/491/80
HypertensionVascular disorders9/7122/1433/494/80
Back painMusculoskeletal and connective tissue disorders9/7120/1435/494/80
Alanine aminotransferase increasedInvestigations9/7120/1436/495/80
Decreased appetiteMetabolism and nutrition disorders9/713/1434/492/80
Oedema peripheralGeneral disorders9/7110/1432/495/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)Total
Mean67.7 ± 7.7568.2 ± 8.368 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)Total
Female000
Male71143214
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)Total
Asian71143214
Region of Enrollment
Region of Enrollment(Participants)Placebo + Prednisone (Double-blind)Abiraterone Acetate + Prednisone (Double-blind)Total
China71143214
08

Study locations

11 sites
  • Beijing, China
  • Changsha, China
  • Chongqing, China
  • Guangzhou, China
  • Hangzhou, China
  • Nanjing, China
  • Shanghai, China
  • Su Zhou, China
  • Tianjin, China
  • Wenzhou, China
  • Wuhan, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Jun 2014, 22 months.

Results were first posted in Jul 2019, 5 years after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 22 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2012
First posted
Sep 27, 2012
StartActual
Aug 9, 2012
Primary completionActual
Jun 20, 2014
CompletionActual
May 8, 2018
Results first posted
Jul 18, 2019
Last update
Jul 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01695135
Responsible party
Sponsor
First posted
Sep 27, 2012
Start date
Aug 9, 2012
Primary completion
Jun 20, 2014
Completion
May 8, 2018
Results posted
Jul 18, 2019
Last update
Jul 18, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion